OPGN (OpGen Inc) Bathi resik

OpGen, Inc. remains in a risk zone due to a lack of funds and the prolonged bankruptcy of its European subsidiaries. Business development relies on the sale of Acuitas systems for antibiotic resistance analysis in clinics. Diagnostic automation via molecular platforms accelerates the delivery of diagnoses. The company's net income figure reflects the current balance of demand, with the latest mark standing at 0.00.

For OpGen, Inc. (OPGN), analyzing net proceeds is critical, as declining demand for diagnostics and a high proportion of fixed costs are blocking the business from reaching the break-even point. The company's quarterly profit dynamics reflect actual cash flow net of all expenses, allowing investors to distinguish genuine growth from a speculative rally and avoid overpaying for the asset.